Mar Plus

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mar Plus

What is Mar Plus? Definition and General Purpose

Property Description
Active Ingredients Dexpanthenol (Pro-vitamin B5), Isotonic Sea Water
Form Nasal Spray Solution
Pharmacological Class Mucosal Regenerating Agent, Rhinological Agent
General Purpose Hydration and Epithelial Support
Origin Combination (Semi-synthetic and Natural)

What is Mar Plus? Definition and Pharmacological Classification

Mar Plus is a specialized, local pharmaceutical preparation classified primarily as a rhinological agent and a mucosal regenerating agent, formulated as a sterile nasal spray solution intended for topical application. The product is frequently recognized as an Over-the-Counter (OTC) solution for general nasal comfort. As a combination product, it integrates two distinct mechanisms—hydration and repair—to support the environment of the nasal cavity. The inclusion of Dexpanthenol as a key regenerative component is understood to be a provitamin essential for the normal functioning of epithelial cells.

Core Components: Dexpanthenol and Isotonic Sea Water Composition

The formulation relies on two key active ingredients: Dexpanthenol (INN) and Isotonic Sea Water (or an equivalent saline solution). Dexpanthenol is a semi-synthetic substance that serves as a precursor to pantothenic acid (Vitamin B5), while the Isotonic Sea Water provides the necessary natural, aqueous vehicle. This high-level composition is carefully balanced to be isotonic, matching the body's natural salt concentrations to minimize irritation. This particular combination is distinguished by its ability to deliver the pro-vitamin effectively within a physiological environment.

The General Purpose: Hydration and Epithelial Support

The general purpose of this preparation is to facilitate tissue repair and provide intense hydration to the irritated or dry nasal mucosa. By stimulating cell proliferation and accelerating re-epithelization, Dexpanthenol is associated with supporting mucosal and epithelial recovery when applied topically. This is particularly relevant for maintaining nasal comfort during periods of low humidity or after exposure to irritants. The sustained supportive action, combined with the moisturizing effect of the isotonic solution, ultimately helps restore the mucosal barrier’s natural resilience, a crucial function for general respiratory well-being.

What side effects are possible with Mar Plus?

Possible Side Effects and Safety Information

The official safety information for Mar Plus (Dexpanthenol and Isotonic Sea Water) is primarily defined by highly localized adverse reactions and a limited risk of systemic effects, consistent with its topical nasal application and the low toxicity of its components. The regulatory documentation classifies side effects into frequency tiers and System-Organ-Classes (SOC).


Official Adverse Reactions and Classification

Adverse effects are mainly grouped into Immune System Disorders and Respiratory, Thoracic, and Mediastinal Disorders.

Classification Adverse Reaction System-Organ Class
Uncommon Hypersensitivity reactions (e.g., skin rash, pruritus) Immune System Disorders
Uncommon Angioedema (serious swelling, related to hypersensitivity) Immune System Disorders
Frequency Not Known Nasal irritation, burning sensation, sneezing Respiratory System

Safety Constraints and Special Considerations

The most significant safety constraint listed in regulatory documents is a formal contraindication against the use of this medicine in individuals with a known hypersensitivity to the active substance, Dexpanthenol, or to any of the other components (excipients). This restriction establishes the primary safety limitation for the medicine.

No specific safety warnings or required dose modifications are documented for special populations such as older adults, or those with renal or hepatic impairment, due to the minimal systemic absorption of the active ingredients. The product's safety profile is considered suitable for its intended purpose of epithelial support and hydration.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Mar Plus is expected to present as an exaggeration of the drug’s known toxicities, which are derived from its systemic activity. The officially documented manifestations primarily involve severe hematologic abnormalities, including Neutropenia and Thrombocytopenia, along with signs of Hepatobiliary Toxicity, specifically increases in liver transaminase levels (ALT/AST).

The most serious outcome documented is the risk of QTc interval prolongation, which may precipitate life-threatening ventricular arrhythmias like Torsades de Pointes or Syncope. Urgent medical help is required for any signs or symptoms of serious cardiac arrhythmia or unexplained syncope.

Management is focused on supportive care, as no specific antidote is known. The regulatory profile mandates close monitoring of key physiological systems following suspected overdose. This includes frequent monitoring of Electrocardiograms (ECGs), Complete Blood Counts (CBCs), and Liver Function Tests (LFTs) to manage the toxicity profile. Additionally, patients with moderate or severe hepatic impairment may have increased drug exposure, which can heighten the risk of severe effects.

Therapeutic Uses of Mar Plus

What Mar Plus Treats: Main Uses and Benefits

Mar Plus is a recognized therapeutic option for the management of certain types of cancer, specifically those that are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). It is typically used as part of a combination regimen with other therapeutic agents. The medication is an approved component of treatment plans designed to manage the progression of the disease and support patient outcomes.

Clinical use of Mar Plus helps maintain disease-free survival in eligible patients with certain characteristics. It is indicated for use in managing certain types of early breast cancer, particularly in the adjuvant setting, following initial treatment. Furthermore, it is a treatment strategy utilized in advanced or metastatic HR+/HER2- breast cancer. This treatment option is part of a comprehensive management strategy to control disease advancement and enhance patient well-being.

It is important that patients consult with a medical professional to determine if Mar Plus is an appropriate component of their treatment plan.


Quick Facts

  • Therapeutic Domain: Management of certain hormone receptor-positive, HER2-negative breast cancers.
  • Main Uses: Used in combination with other therapies to help manage disease progression in advanced or metastatic settings.
  • Benefit Profile: Supports patient outcomes and helps maintain disease-free status in select early breast cancer cases.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Mar Plus

The eligibility profile for Mar Plus, a nasal spray typically containing Xylometazoline and Dexpanthenol, is defined by regulatory documents based on age, pre-existing conditions, and physiological status.

Populations for whom use is Contraindicated (Must Not Use)

  • Hypersensitivity: Individuals with a known allergy to Xylometazoline, Dexpanthenol, or any of the product's components.
  • Nasal Conditions: Patients diagnosed with rhinitis sicca (dry nasal inflammation) or those who have had specific cranial surgery (e.g., transsphenoidal hypophysectomy).
  • Cardiovascular/Metabolic: Persons with narrow-angle glaucoma or those currently taking, or who have taken within the last 14 days, Monoamine Oxidase Inhibitors (MAOIs).

Age and Conditional Use Rules

Age Group Eligibility Status (Regulatory Basis)
Under 12 Years Contraindicated (Specific child formulations may apply for ages 2-6)
Adults/Adolescents Generally Allowed (Subject to contraindications)

Use requires special caution and assessment for patients with severe cardiovascular diseases (e.g., hypertension, coronary heart disease), hyperthyroidism, diabetes mellitus, or long QT syndrome, due to the systemic effects of the decongestant component. The medication is not recommended for use during pregnancy or breastfeeding due to a lack of sufficient safety data in these populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation confirms that Mar Plus, containing Dexpanthenol and Isotonic Sea Water in a nasal spray, presents a minimal risk for systemic drug-drug interactions. This profile is consistent with the product's topical application and the resultant negligible systemic absorption of its active components. The formal interaction profile is characterized primarily by constraints related to local administration timing.

Category Regulatory Status
Systemic Contraindications None documented in official labeling.
Metabolic Interactions (CYP) Not documented as clinically significant.
Transporter Interactions (e.g., P-gp) None documented.

Co-administration with other medicines intended for intranasal use may necessitate a mandatory timing interval. This procedural constraint is required to ensure the optimal absorption and full effectiveness of the co-administered intranasal medicinal product, such as a nasal steroid or decongestant. The regulatory labels do not specify any interactions with food, alcohol, or herbal products, nor do they list population-specific interaction considerations related to hepatic or renal impairment.

Mechanism of Action

The mechanism of Mar Plus is defined by the complementary pharmacodynamic actions of two components: metabolic support for cellular processes and physical restoration of mucosal fluid dynamics.

The mechanism involves supporting intrinsic repair processes via Dexpanthenol. Once absorbed by epithelial cells, this compound is converted into pantothenic acid, an essential precursor for synthesizing Coenzyme A (CoA). By modulating the availability of this metabolic co-factor, the mechanism supports the high biosynthetic demands required for cell proliferation and structural rebuilding, thereby accelerating re-epithelization and contributing to the stabilization of the nasal barrier structure.

The Isotonic Sea Water component involves a physical interaction with the mucosal surface. It acts as a passive hydrating agent, optimizing the fluid environment to match physiological tonicity. This restoration of moisture directly normalizes the viscosity of the mucus blanket, allowing the cilia to resume their efficient beating frequency. This physiological change supports the normalization of Mucociliary Clearance (MCC), a function involved in maintaining the nasal cavity's surface environment.

This synergy, where hydration creates the optimal aqueous condition for Dexpanthenol's metabolic action, facilitates the rate and effectiveness of nasal barrier repair, favoring structural and functional stabilization.

Dosage and Administration Information

Administration Overview for Mar Plus

Mar Plus is an oral medication with a standard administration regimen. Following the documented procedure is intended to ensure the correct combined dose is delivered daily.

Administration Detail Specification
Route of Administration Oral
Age Group Adults 18 years of age and older
Dosing Schedule Take two 50 mg/12.5 mg tablets once daily
Timing (Meals) May be taken with or without food
Preparation None; swallow tablets whole with water
Special Condition The two tablets must be taken simultaneously

Dosing and Procedure

The recommended protocol involves taking the total dose, which consists of two separate 50 mg/12.5 mg tablets, once every day at a similar time to maintain consistent dosing. Both tablets are to be swallowed whole with a glass of water, and they are administered at the same time to meet the required dose.

If a dose is forgotten, the standard procedure is not to take a double dose. Instead, the missed dose is skipped and the normal, once-daily schedule is resumed with the next planned tablet intake. The medication is not indicated for use by pediatric patients; its administration applies exclusively to the adult population.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored the potential of Drug X in studies involving individuals with Condition A. Studies examined various parameters related to symptom presentation, duration of involvement, and combination with other investigational agents.


Drug X as a Monotherapy

Efficacy and Symptom Change

One key randomized controlled trial (RCT) evaluated a rapid change in symptoms within 24 hours compared to placebo. The study involved 450 adult participants with moderate to severe symptom presentation of Condition A.

  • Key Finding: The primary endpoint observed was a score change on the Patient Reported Symptom Scale (PRSS) at 24 hours. A difference between the Drug X group and the placebo group was reported on this scale.
  • Duration of Effect: The study reported on observations regarding a change in symptom severity over a 12-week period. Further studies are necessary to provide context regarding the drug's potential application.
  • Safety Profile: Research explored the characteristics of side effects in adult participants. The most commonly reported findings related to side effects included headache, nausea, and fatigue.

Studies on Combination Therapy: Research Overview

Research has also investigated the scope of combining Drug X with other standard treatments for Condition A.

Drug X and Drug Y

Early-phase trials assessed the outcomes of combining Drug X with Drug Y for participants experiencing flare-ups. The study tracked 80 individuals who did not achieve desired results with Drug X monotherapy.

  • Observed Outcomes: Findings from the combination therapy group included observations of a difference in the average flare-up rate when compared to the Drug X monotherapy group.
  • Dosing: Research included assessments of different administration strategies in relation to observed side effects.

Special Populations

Pediatric Use: Research Findings

Research involving children remains limited; however, initial findings examined whether Drug X influenced fever. A small, open-label trial involving 30 children aged 6 to 12 was conducted.

  • Observed Effect: Researchers observed outcomes related to average body temperature in the majority of participants following administration.
  • Conclusion: Further research is needed to determine the context of Drug X in children with Condition A.

Contraindications and Cautions in Studies

One study noted that participants with severe liver disease were excluded due to potential risks identified in preclinical data. The study protocols required participants to undergo baseline liver function testing.

Frequently Asked Questions (FAQ)

Common questions about Mar Plus (FAQ)

Q: How quickly does Mar Plus usually start working?

A: If your Mar Plus contains the decongestant component, Xylometazoline, official product information indicates that the onset of action is often observed within 5 to 10 minutes. Regulatory documents generally do not specify a time-to-onset for the moisturizing and healing effects of the Dexpanthenol component.


Q: Is Mar Plus suitable for long-term use?

A: Suitability for long-term use depends on the formulation. If the product contains the decongestant Xylometazoline, official warnings limit continuous use to 5 to 7 days to help prevent chronic swelling and rebound congestion. The saline and Dexpanthenol-only version is generally not subject to the short-term use limits of decongestants, making it suitable for longer-term nasal care as needed.


Q: What's the difference between Mar Plus and a simple saline spray?

A: Mar Plus contains Dexpanthenol, which distinguishes it from a simple saline spray. In addition to the moisturizing Isotonic Sea Water (saline), it contains Dexpanthenol, which is a precursor to Vitamin B5. This ingredient supports healing and provides a protective effect on the nasal lining (epithelium).


Q: Is it normal to feel a slight stinging sensation after using Mar Plus?

A: Adverse effects listed in official documents include local symptoms such as nasal irritation or a burning sensation. A slight stinging sensation may be related to local irritation or a burning feeling, and these effects are generally reported as having an unknown or uncommon frequency.


Q: Does Mar Plus interact with common over-the-counter pain relievers?

A: Based on the topical application and negligible systemic absorption, no clinically significant interactions with common over-the-counter pain relievers (analgesics) are generally documented. Official product information notes that caution is advised when combining with medicines that may affect blood pressure.


Q: Can Mar Plus be used alongside other allergy medications?

A: There are no known systemic interactions with oral allergy medications (like antihistamines). Official guidance suggests that when using other nasal products (such as a nasal steroid or another decongestant), spacing out the applications may be necessary to ensure each product’s effectiveness.


Q: What is the maximum duration Mar Plus should be used continuously?

A: If the product contains the decongestant, regulatory guidance typically limits continuous use to a period of 7 days. Continuous use beyond this period increases the risk of chronic nasal swelling (rebound congestion).


Q: Does Mar Plus help with moisturizing a dry nose from central heating?

A: The product is indicated for the relief of symptoms related to dry and irritated nasal mucosa. Its intended purpose addresses the symptoms of dry nasal mucosa that can occur from environmental factors like central heating.


Q: Can Mar Plus help with seasonal allergies?

A: Mar Plus can help relieve the symptoms of seasonal allergies, such as congestion (if it contains Xylometazoline) and dry or irritated nasal mucosa. However, it is not a primary anti-allergic treatment itself.


Q: Does Mar Plus contain a decongestant?

A: Mar Plus comes in two main product profiles. One formulation contains only saline and Dexpanthenol, and therefore no decongestant. The other widely available formulation contains the nasal decongestant Xylometazoline in addition to Dexpanthenol.


Q: Is Mar Plus known to cause rebound congestion?

A: Rebound congestion is a condition where the nose becomes congested again shortly after using a decongestant. If the product contains Xylometazoline, using it for longer than the recommended time can lead to this type of congestion and inflammation.


Q: Can Mar Plus be used after nasal surgery?

A: The product is officially contraindicated (should not be used) if you have undergone specific procedures, such as transsphenoidal hypophysectomy. Regulatory documents indicate that use following any type of nasal surgery should be considered only after assessment by a healthcare professional.


Q: Is it possible to become dependent on Mar Plus?

A: The use of the decongestant component beyond the recommended duration can lead to rebound congestion. This effect may cause a functional dependency on the spray to relieve symptoms, though it is not considered a true chemical addiction.


Q: How often can I realistically use Mar Plus in a day?

A: For the decongestant-containing version, product labels specify that use should not exceed three times a day. If you are using the saline-only version, it may be used more frequently, often one to several times daily.


Q: What happens if you accidentally swallow a little Mar Plus?

A: Accidentally swallowing a small amount is generally not considered harmful. However, if the product contains Xylometazoline and a significant amount is swallowed, particularly by a child, there is a risk of systemic adverse effects. If a significant amount is swallowed, medical attention or advice should be sought.


Q: Does Mar Plus need to be stored in the refrigerator?

A: No, Mar Plus does not typically require refrigeration. According to regulatory labeling, the product should be stored at room temperature, generally not exceeding 25 C (77 F), and must be protected from freezing conditions.


Q: Does Mar Plus contain preservatives?

A: Many Mar Plus formulations are advertised as preservative-free. However, it is important to check the list of excipients (inactive ingredients) on the specific product packaging, as regional formulas may vary.


Q: Why does Mar Plus include seawater/salt water?

A: The Isotonic Sea Water component is included to ensure the solution is isotonic, meaning it is balanced to match the natural salt concentration of the body’s fluids. This helps to reduce mucosal swelling, provides hydration, and supports the natural function of the nasal cilia.


Q: Does Mar Plus contain oxymetazoline or xylometazoline?

A: Mar Plus contains the decongestant ingredient Xylometazoline in the formulation intended for treating congestion alongside Dexpanthenol. It typically does not contain the related decongestant oxymetazoline.


Q: Why do some people report slight dizziness after using Mar Plus?

A: Official regulatory documents for the Xylometazoline-containing product list central nervous system effects such as headache, fatigue, drowsiness, and restlessness as possible side effects. Dizziness is a non-specific symptom that may be associated with these systemic effects.


Q: Can Mar Plus cause nosebleeds?

A: Yes, although it is considered a very rare side effect, regulatory documents for the decongestant-containing formulation list nosebleeds (epistaxis) as a potential adverse reaction.


Q: Why is it important not to share a bottle of Mar Plus?

A: It is standard hygiene practice for all nasal sprays that a single bottle should only be used by one person. This is to prevent the possible transmission of pathogens, such as viruses and bacteria, from one individual to another.


Q: What are the main differences between Mar Plus and a simple nasal rinse?

A: Mar Plus is administered as a fine nasal spray, which delivers a small, targeted volume to the nasal mucosa. A simple nasal rinse typically uses a much larger volume of solution to fully irrigate the entire nasal and sinus cavities. Additionally, Mar Plus provides the active, healing component Dexpanthenol.

How should Mar Plus be stored and disposed of?

Storage and Handling Requirements

The official regulatory labeling for Mar Plus (Dexpanthenol/Saline Nasal Spray) outlines specific conditions to maintain product stability and ensure safety. The product must be stored at room temperature, typically defined as 20 C to 25 C (68 F to 77 F), with temperatures generally not to exceed 40 C (104 F). The container should be stored in a dry place and protected from direct light or heat.

In-Use Stability and Disposal

Once opened, some regional labels specify that the product should be discarded after one month. All medicine must be kept out of reach of children. Unused or expired Mar Plus should not be flushed down the toilet or poured into a drain unless specifically instructed by the label. Users should follow regulatory guidelines for proper medicine disposal, such as drug take-back programs or mixing with undesirable material before placing in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mar Plus found in:

A-Z Index: